Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 23 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

9%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (5)
P 1 (8)
P 2 (3)
P 4 (2)

Trial Status

Not Yet Recruiting10
Recruiting7
Active Not Recruiting2
Completed2
Unknown1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07021092Not ApplicableActive Not Recruiting

PERSON-CENTERED APPROACHES TO VIREMIA: CONNECTION, RAPPORT, AND ENGAGEMENT STUDY

NCT07215468Phase 2Active Not RecruitingPrimary

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

NCT07725042RecruitingPrimary

Analyses of Newly Diagnosed HIV Infection in Hong Kong

NCT07719491Phase 1Not Yet RecruitingPrimary

Study of GS-0415 and How It Works in People With HIV

NCT07698600Phase 1Not Yet RecruitingPrimary

A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV

NCT07476339Phase 4Recruiting

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

NCT07692932Not ApplicableNot Yet RecruitingPrimary

Study of Combined GARP:TGF-β1/PD-1 Blockade as a Shock-and-kill Strategy in HIV-1 Cure

NCT07392372Phase 1RecruitingPrimary

A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV

NCT07655141Phase 1Not Yet RecruitingPrimary

Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2)

NCT07655128Phase 1Not Yet RecruitingPrimary

Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life

NCT07643948RecruitingPrimary

Impacts of HIV Treatment Regimens on Archived Drug Resistance

NCT07637942Not Yet RecruitingPrimary

Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

NCT07618507Not ApplicableCompleted

Resistance Profile to Antiretroviral Medications in Individuals Living With HIV Who Failed a First-Line Regimen With Tenofovir / Lamivudina and Dolutegravir in Brasil

NCT07621510Not ApplicableNot Yet RecruitingPrimary

Integrating iSYV Within HIV Clinical Care for Youth Living With HIV in Tanzania

NCT07584369Phase 4Not Yet RecruitingPrimary

Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study

NCT07563309Not ApplicableRecruitingPrimary

A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test

NCT07181486Phase 1RecruitingPrimary

Safety Study of MucoCept-CVN

NCT07384624Phase 1Not Yet Recruiting

Combining Latency Reversing Agents to Address the HIV Reservoir

NCT07186244Recruiting

Prevention ICONA Dedicated Ensemble

NCT06637813Not Yet RecruitingPrimary

Establishment of a Database of HIV Subjects Initiating or Simplifying Dual Therapy With Dolutegravir/Lamivudine

Scroll to load more

Research Network

Activity Timeline